Gene Profiling in Recurrent Small Cell Lung Cancer
No abstract available
CONCLUSIONS circ_100395 appears to be a promising therapeutic target for liver cancer. PMID: 31421050 [PubMed - in process]
Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer Interventions: Drug: Durvalumab; Procedure: Surgery; Radiation: Radiotherapy Sponsors: Alliance Foundation Trials, LLC.; AstraZeneca Not yet recruiting
Conditions: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJC C v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 I...
CONCLUSION: The number of patients with COPD registered in primary health care was similar in all investigated years. Lung cancer as comorbidity was found in a significantly smaller number of these patients. PMID: 31424648 [PubMed - in process]
CONCLUSIONS: Higher expression of microRNA-19a promotes proliferative and migratory abilities of NSCLC cells by target inhibiting PTEN expression. PMID: 31424647 [PubMed - in process]
Authors: P Sotiropoulos G, Kotopouli M, Karampela I, Christodoulatos GS, Antonakos G, Marinou I, Vogiatzakis E, Lekka A, G Papavassiliou A, Dalamaga M Abstract PURPOSE: Plasminogen activator inhibitor-1 (PAI-1) participates in thrombotic, fibrinolytic, inflammatory and metabolic cascades. Since previous studies have focused on tissue and blood level concentrations, our goal was to investigate for the first time the independent relationship between plasma PAI-1 activity in resectable non small cell lung cancer (NSCLC) taking into consideration its several interfaces and study its diagnostic and prognostic potential....
CONCLUSIONS: Chrysoeriol considerably and selectively suppresses the growth of lung cancer in vitro and in vivo and may prove beneficial in the management of this disease. PMID: 31424645 [PubMed - in process]
Authors: Liu S, Chen J, Zhang T, Chen H Abstract PURPOSE: Accounting for 25% of all cancers and 20% of the cancer related-mortality, lung cancer is one of the devastating types of malignancies. The main obstacles for successful lung cancer manipulation include late diagnosis, dearth of safer chemotherapy and lack of potent therapeutic targets. Evidence indicates that microRNAs (miRs) may prove essential therapeutic targets for the management of deadly diseases, including cancer. Herein the role of miR-133 was investigated in lung cancer and the therapeutic potential of miR-133 was explored. METHODS: qRT-PCR was...
CONCLUSIONS: H19 polymorphism rs2067051 and rs217727 might influence NSCLC susceptibility and the mechanism warrants further exploration. PMID: 31424642 [PubMed - in process]
CONCLUSIONS: In conclusion, the current results strongly indicate that Curzerenone may prove a potential anticancer drug candidate against drug-resistant lung cancer. PMID: 31424641 [PubMed - in process]